Showing 1 - 10 of 815
Background: The Food and Drug Administration Modernization Act (FDAMA) of 1997, Best Pharmaceuticals for Children Act (BPCA) of 2002 and Pediatric Research Equity Act of 2007 provide an extended period of 6 months of marketing exclusivity (i.e. patent extension) to prescription drug...
Persistent link: https://www.econbiz.de/10010614273
Comparative effectiveness research is expected to play an important role in future clinical and policy decision making in the US; however, the application of comparative effectiveness methodologies to child health requires special attention to aspects of health and healthcare that are specific...
Persistent link: https://www.econbiz.de/10010556695
Following a licence extension to include those aged 6-11 years, the National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of omalizumab (Novartis Pharmaceuticals UK) to submit evidence for the clinical and cost effectiveness of this drug for patients with severe...
Persistent link: https://www.econbiz.de/10010579449
Community-acquired pneumonia (CAP) is a common cause of morbidity and mortality and is associated with the consumption of considerable health resources worldwide. Initial treatment of patients with CAP is often empirical. Growing concern about the increasing prevalence of atypical organisms is...
Persistent link: https://www.econbiz.de/10005590122
Differences between children and adults have both technical and ethical implications for the design, interpretation and employment of economic analyses of health-related programmes. Even though policy makers increasingly turn to economic analyses to inform decisions about resource allocation,...
Persistent link: https://www.econbiz.de/10005590364
Background: Lennox-Gastaut syndrome (LGS) is a catastrophic childhood form of epilepsy. The syndrome is characterized by mental impairment, frequent seizures of multiple types that are particularly resistant to treatment, and high rates of seizure-related injury. With the introduction of newer,...
Persistent link: https://www.econbiz.de/10008521839
Objective: To estimate the pharmacoeconomic impact for the French Social Security System of preventing recurrent acute rhinopharyngitis (RARP) in at-risk children with OM-85 BV, an immunostimulating agent indicated for the prevention of recurrences. Design: A decision-analysis model. The...
Persistent link: https://www.econbiz.de/10005243125
Background:Background: About 7% of children and adolescents are diagnosed with attention-deficit/hyperactivity disorder (ADHD) in the US. Patients with ADHD who are intolerant of or do not have an optimal response to stimulants often use non-stimulants as alternative therapies. Guanfacine...
Persistent link: https://www.econbiz.de/10010585886
While pneumococcal conjugate vaccines have shown to be highly effective against invasive pneumococcal disease, their potential effectiveness against acute otitis media (AOM) might become a major economic driver for implementing these vaccines in national immunization programmes. However, the...
Persistent link: https://www.econbiz.de/10010614297
Persistent link: https://www.econbiz.de/10010614321